Roche (SWX: ROG), the Swiss pharmaceutical giant, has reaffirmed its long-term commitment to the Chinese market with plans to significantly increase investments across the medical industry value chain. This strategic expansion was announced during the company’s 30-year anniversary celebration in China, highlighting its dedication to the region.
The company’s novel influenza treatment, Xofluza (baloxavir marboxil), is also set to transition to local manufacturing within the year, a move that underscores Roche’s commitment to serving the Chinese market with innovative medicines.
Roche’s integrated medical industry value chain expansion includes early research and development, drug development, manufacturing, open collaboration, and commercial operations. As the first multinational corporation to establish a presence in Zhangjiang Hi-tech Park in Shanghai, Roche has introduced 29 products across 8 major therapeutic areas in China.
Furthermore, over 10 domestic innovative companies have joined Roche’s China accelerator program, initiated in 2021, leading to more than 10 early-stage research and development partnerships, which further strengthens the company’s position in fostering innovation in China.- Flcube.com
